A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation

Nature Medicine

Volumn 2, Issue 7, 1996, Pages 804-810

  Lutzker, Stuart G ^a,b   Levine, Arnold J ^a  

^a PRINCETON UNIVERSITY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; DNA DAMAGE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TERATOCARCINOMA; TESTIS TUMOR;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; DNA DAMAGE; MALE; MICE; MICE, INBRED BALB C; MUTATION; TERATOMA; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; MURINAE;

EID: 0029944241     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0796-804     Document Type: Article

References (57)

1. Pottern, L. & Goedert, J. Principles and Management of Testicular Cancer (ed. Javadpour, N.) 108-119 (Thieme, New York, 1986).
2. Champlin, R. & Gale, R. Acute myelogenous leukemia: Recent advances in therapy. Blood 69, 1551-1562 (1987).
3. Harris, C.C. & Hollstein, M. Clinical implications of the p53 tumor-suppressor gene. New Engl. J. Med. 329, 1318-1327 (1993).
4. Levine, A.J. et al. The role of the p53 tumor suppressor gene in tumorigenesis. Br. J. Cancer 69, 409-416 (1994).
5. Oren, M., Reich, N.C. & Levine, A.J. Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny. Mol. Cell. Biol. 2, 443-149 (1982).
6. Bartkova, J. et al. p53 protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia. Int. J. Cancer 49, 196-202 (1991).
7. Lewis, D., Sesterhenn, I., McCarthy, W. & Moul, J. Immunohistochemical expression of p53 tumor suppressor gene protein in adult germ cell testis tumors: Clinical correlation in stage I disease. J. Urol. 152, 418-123 (1994).
8. Riou, G. et al. The p53 and mdm-2 genes in human testicular germ-cell tumors. Mol. Carcinog. 12, 124-131 (1995).
9. Heimdal, K. et al. No germline TP3 mutations detected in familial and bilateral testicular cancers. Genes Chromosom. Cancer 6, 92-97 (1993).
10. Peng, H.Q. et al. Mutations of the p53 gene do not occur in testis cancer. Cancer Res. 53, 3574-3578 (1993).
11. Murty, V.V.V.S. et al. Allelic loss and somatic differentiation in human male germ cell tumors. Oncogene 9, 2245-2251 (1994).
12. Schenkman, N.S. et al. Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors. J. Urol. 154, 617-621 (1995).
13. Pennica, D. et al. The amino acid sequence of murine p53 determined from a CDNA clone. Virology 134, 477-483 (1984).
14. Reich, N.C., Oren, M. & Levine, A.J. Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol. Cell. Biol. 3, 2143-2150 (1983).
15. Momand, J., Zambetti, G.P., Olson, D.C., George, D. & Levine, A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell 69, 1237-1245 (1992).
16. Oliner, J.D., Kinzler, K.W., Meltzer, P.S., George, D. & Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358, 80-83 (1992).
17. Finlay, C.A. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell. Biol. 13, 301-306 (1993).
18. Fakharzadeh, S.S., Trusko, S.P. & George, D.L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10, 1565-1569 (1991).
19. Gannon, J.V., Greaves, R., Iggo, R. & Lane, D.P. Activating mutations in p53 produce common conformational effects: A monoclonal antibody specific for the mutant form. EMBO J. 9, 1595-1602 (1990).
20. Olson, D. et al. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 8, 2353-2360 (1993).
21. Barak, Y., Juven, T., Haffner, R. & Oren, M. mdm2 expression is induced by wild type p53 activity. EMBO J. 12, 461-168 (1993).
22. Haines, D.S., Landers, J.E., Engle, L.J. & George, D.L. Physical and functional interaction between wild-type p53 and mdm-2 proteins. Mol. Cell. Biol. 14, 1171-1178 (1994).
23. Michalovitz, D., Halevy, O. & Oren, M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62, 671-680 (1990).
24. Wu, X., Bayle, J.H., Olson, D. & Levine, A.J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7, 1126-1132 (1993).
25. Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311 (1991).
26. 1 arrest and apoptosis. Cancer Res. 54, 1169-1174 (1994).
27. Perry, M.E., Piette, J., Zawadzki, J., Harvey, D. & Levine, A.J. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc. Natl. Acad. Sci. USA 90, 11623-11627 (1993).
28. Shaw, P. et al. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. USA 89, 4495-1499 (1992).
29. Yonish-Rouach, E. et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352, 345-347 (1991).
30. Strickland, S., Smith, K. & Marotti, K. Hormonal induction of differentiation in teratocarcinoma stem cells: Generation of parietal endoderm by retinoic acid and dibutyryl cAMP. Cell 21 (1980).
31. Lucje-Huhle, C. & Herrlich, P. Retionic-acid-induced differentiation prevents gene amplification in teratocarcinoma stem cells. Int. J. Cancer 47, 461-465 (1991).
32. Livingstone, L.R. et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70, 923-935 (1992).
33. Harvey, M., McArther, M., Montgomery, C., Bradley, A. & Donehower, L. Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J. 7, 938-943 (1993).
34. Rotter, V. et al. Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome. Proc. Natl. Acad. Sci. USA 90, 9075-9079 (1993).
35. Rao, L. et al. The adenovirus E1A proteins induce apoptosis which is inherited by the E1B 19 Kd and Bcl proteins. Proc. Natl. Acad. Sci. USA 89, 7742-7746 (1992).
36. Hupp, T., Meek, D., Midgley, C.A. & Lane, D. Regulation of the specific DNA binding function of p53. Cell 71, 875-886 (1992).
37. Thut, C.J., Chen, J.L., Klemin, R. & Tjian, R. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 267, 100-104 (1995).
38. Lu, H. & Levine, A.J. Human TAF-31 is a transcriptional coactivation of the p53 protein. Proc. Natl. Acad. Sci. USA 92, 5154 (1995).
39. Clarke, A.R. et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849-852 (1993).
40. Lotem, J. & Sachs, L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 82, 1092-1096 (1993).
41. Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B.A. & Jacks, T. p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 362, 847-849 (1993).
42. Evan, G.I. et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69, 119-128 (1992).
43. Hermeking, H. & Eick, D. Mediation of c-Myc-induced apoptosis by p53. Science 265, 2091-2093 (1994).
44. Debbas, M. & White, E. Wild-type p53 mediates apoptosis by E1A which is inhibited by E1B. Genes Dev. 7, 546-554 (1993).
45. Wu, X. & Levine, A.J. p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA 91, 3602-3606 (1994).
46. Canman, C., Gilmer, T., Coutts, S. & Kastan, M. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev. 9, 600-611 (1995).
47. Campisi, J., Gray, H., Pardee, A., Dean, M. & Sonnenshein, G. Cell cycle control of c-myc but not c-ras expression is lost following transformation. Cell 36, 241-247 (1984).
48. Imperiale, M., Kao, H.-T., Feldman, L., Nevins, J. & Strickland, S. Common control of the heat shock gene and early adenovirus-genes: Evidence for a cellular e1A-like activity. Mol. Cell. Biol. 4, 867-874 (1984).
49. Strohmeyer, T. et al. Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. Proc. Natl. Acad. Sci. USA 88, 6662-6666 (1991).
50. Hen, R., Borrelli, E., Fromental, D., Sassone-Corsi, P. & Chambon, P. A mutated polyoma virus enhancer which is active in undifferentiated embryonal carcinoma cells is not repressed by adenovirus-2 E1A products. Nature 321, 249-251 (1986).
51. Slack, R.S. et al. Cells differentiating into neuroectoderm undergo apoptosis in the absence of functional retinoblastoma family proteins. J. Cell Biol. 129, 779-788 (1995).
52. Langley, R., Palayoor, S., Coleman, C. Bump, E. Radiation-induced apoptosis in F9 teratocarcinoma cells. Int. J. Radiat. Biol. 65, 605-610 (1994).
53. Schmid, P., Lorenz, A., Hameister, H. & Montenarh, M. Expression of p53 during mouse embryogenesis. Development 113, 857-865 (1991).
54. Mora, P, Chandrasekaran, K. & McFarland, V. An embryo protein induced by SV40 virus transformation of mouse cells. Nature 288, 722-724 (1980).
55. Nicol, C., Harrison, M., Laposa, G., Gimelshtein, I. & Wells, P. A teratologic suppressor role for p53 in benzo[a]pyrene-treated transgenic p53-deficient mice. Nature Genet. 10, 181-187 (1995).
56. Marechal, V., Elenbaas, B., Piette, J., Nicolas, J.-C. & Levine, A.J. The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol. Cell. Biol. 14, 7414-7420 (1994).
57. Chomczynski, P. & Sacchi, N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156-159 (1987).